Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study.

ABSTRACT:

Background

The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).

Aim

To report participant characteristics and real-world safety and effectiveness of emicizumab in ATHN 7.

Methods

ATHN 7 is a prospective observational cohort study conducted across 26 American Thrombosis and Haemostasis Network (ATHN)-affiliated sites. People with HA receiving emicizumab were eligible for inclusion in this analysis. Clinical information was collected quarterly through participant interview and medical record review. Safety was evaluated by documenting

SUBMITTER: Buckner TW 

PROVIDER: S-EPMC12904170 | biostudies-literature | 2026 Jan-Feb

REPOSITORIES: biostudies-literature